BioSpace News Archive

Lumicell, Inc. today announced a New Drug Application (NDA) for its LUMISIGHT™ Optical Imaging Agent has been submitted to the U.S. Food and Drug Administration (FDA).

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening.

Diabeloop, a pioneer in Automated Insulin Delivery, will collaborate with leading global healthcare company, Novo Nordisk.

Selecta Biosciences, Inc. and Sobi®, announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials to determine safety and efficacy of two different dose levels of SEL-212 in adult patients with chronic refractory gout.

X4 Pharmaceuticals reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted key 2022 events and expected upcoming milestones.

Vektor Medical announced that use of the vMap® arrhythmia mapping system during complex atrial fibrillation ablation was associated with significantly improved freedom from atrial arrhythmias compared with standard-of-care pulmonary vein isolation.

Disc Medicine, Inc. announced a collaboration with the National Heart Lung and Blood Institute of the National Institutes of Health to evaluate bitopertin, a therapeutic candidate designed to modulate heme biosynthesis, in a phase 2 clinical study of patients with Diamond-Blackfan anemia.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that its SNAP-CAR technology was highlighted in a peer-reviewed article published in the Journal of Translational Medicine.

EpicentRx Inc. (“EpicentRx”), a clinical stage biopharmaceutical company, announced today the publication of a review article on its small molecule, RRx-001, a direct NLRP3 inflammasome inhibitor with activity in cancer, neurodegenerative diseases and other inflammatory conditions.

Mispro Biotech Services, North America’s pioneering contract vivarium organization, is proud to announce its 20th anniversary and brand refresh to commemorate the occasion.